Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415–1418
Category: Chronic myeloid leukaemia
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia
Eradication of leukaemia stem and progenitor cells Mathematical models of CML and TFR are often built on assumptions about haematopoiesis that may or may not…